New approaches to molecular monitoring in CML (and other diseases)-Reference-Cited by-同舟云学术

New approaches to molecular monitoring in CML (and other diseases)

Published:2019-09-18 Issue:19 Volume:134 Page:1578-1584
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Radich Jerald¹²,Yeung Cecilia¹²,Wu David²

Affiliation:

1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and

2. Department of Pathology, University of Washington School of Medicine, Seattle, WA

Abstract

In a review article, the authors discuss the present and future of molecular testing in chronic myeloid leukemia (CML) as a paradigm of the evolution of technologies assisting in better diagnosis, risk stratification, and response monitoring of leukemia and other cancers.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/19/1578/1505327/bloodbld2019000838c.pdf

Reference59 articles.

1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

2. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia [published correction appears in Leukemia. 2010;24(5):1102];Hochhaus;Leukemia,2009

3. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib;Hughes;Blood,2014

4. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION);Jabbour;Blood,2014

5. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia;Kantarjian;N Engl J Med,2010

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long non-coding RNA PXN-AS1 promotes glutamine synthetase-mediated chronic myeloid leukemia BCR::ABL1-independent resistance to Imatinib via cell cycle signaling pathway;Cancer Cell International;2024-05-29

2. Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response;2024-04-05

3. Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions;Current Hematologic Malignancy Reports;2024-02-23

4. Identification of ubiquitination-related hub genes in chronic myeloid leukemia cell by bioinformatics analysis;Journal of Cancer;2024

5. Exploration of treatment‐free remission in CML, based on molecular monitoring;Cancer Medicine;2023-12-22